Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945187 | 0.82 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL378846 | 0.82 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL573864 | 0.78 | MAOB (0.53) | TRPV4MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL30919072 | 0.76 | TRPV4 (0.61) | TRPV4MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL57346 | 0.76 | TRPV4 (0.61) | TRPV4MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL1267080 | 0.76 | ESR2 (0.44) | CA3CA6CA9CA14AR | |
| SCHEMBL21131569 | 0.76 | TRPV4 (0.45) | TRPV4MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL28843641 | 0.75 | AR (0.41) | CA9ARPGRESR2 | |
| SCHEMBL28161686 | 0.75 | ESR1 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL3027689 | 0.74 | CA12 (0.48) | CA3CA6CA9CA14AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9143139-A | — | — | None | — | — | JP | disclosed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4615578-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | EMPRESS THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| JP-H09143139-A | PRODUCTION OF CYANOFLUOROPHENOL | TOHKEM PROD:KK | 1997-06-03 | — | — | JP | disclosed |
| US-5264538-A | Cyclic poly(aryl ether) oligomers | THE DOW CHEMICAL COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| US-5264520-A | Polymerization of cyclic poly(aryl ether) oligomers | THE DOW CHEMICAL COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0413257-A2 | Cyclic poly(aryl ether) oligomers, a process for preparation thereof, and polymerization of cyclic poly (aryl ether) oligomers | THE DOW CHEMICAL COMPANY (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | CA3 3550/4885CA6 2288/4885CA5A 1121/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CA3 1575/4885CA6 2043/4885CA5A 897/4885 |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SI, VIP, APC | CA3 4131/4885CA6 576/4885CA5A 3216/4885 |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | CA3 4689/4885CA6 4668/4885CA5A 3101/4885 |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | CA3 2797/4885CA6 3228/4885CA5A 368/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | CA3 4689/4885CA6 4668/4885CA5A 3101/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | CA3 4689/4885CA6 4668/4885CA5A 3101/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | CA3 3652/4885CA6 3719/4885CA5A 1774/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CA3 4182/4885CA6 2987/4885CA5A 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.